产品
编 号：F746322
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1628814-88-9
产品详情
生物活性：
Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.
体内研究：
Vobarilizumab (0.4-10 mg/kg，静脉注射) 抑制食蟹猴中 hIL-6 诱导的炎症。Vobarilizumab (0.4-10 mg/kg，静脉注射) 通过与食蟹猴的血清白蛋白结合显示出长期暴露。Animal Model:hIL-6-induced inflammation in cynomolgus monkey
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
Administration:Intravenous injection (i.v.)
Result:Inhibited the acute phase response parameters: plasma levels of C-reactive protein (CRP), fibrinogen and platelets.
Animal Model:Cynomolgus monkeys
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
Administration:Intravenous injection (i.v.)
Result:Pharmacokinetic parameters of Vobarilizumab dose (mg/kg) T1/2 dominant (day) AUCinf (μg/day/mL) CL (mL/day/kg) Vss (mL/kg)
0.4 (i.v.)1.7316.324.8 42.8
2 (i.v.)5.0193 10.453.7
10 (i.v.)6.611136 982.7
体外研究：
Vobarilizumab 显示出对 sIL-6R 的优先结合亲和力 (与 mIL-6R 相比) 。Vobarilizumab (0-10 nM) 阻断重组 hIL-6 与重组 hsIL-6R 的相互作用。Vobarilizumab (0-100 nM) 可抑制 TF-1 细胞的增殖。
Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.
体内研究：
Vobarilizumab (0.4-10 mg/kg，静脉注射) 抑制食蟹猴中 hIL-6 诱导的炎症。Vobarilizumab (0.4-10 mg/kg，静脉注射) 通过与食蟹猴的血清白蛋白结合显示出长期暴露。Animal Model:hIL-6-induced inflammation in cynomolgus monkey
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
Administration:Intravenous injection (i.v.)
Result:Inhibited the acute phase response parameters: plasma levels of C-reactive protein (CRP), fibrinogen and platelets.
Animal Model:Cynomolgus monkeys
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
Administration:Intravenous injection (i.v.)
Result:Pharmacokinetic parameters of Vobarilizumab dose (mg/kg) T1/2 dominant (day) AUCinf (μg/day/mL) CL (mL/day/kg) Vss (mL/kg)
0.4 (i.v.)1.7316.324.8 42.8
2 (i.v.)5.0193 10.453.7
10 (i.v.)6.611136 982.7
体外研究：
Vobarilizumab 显示出对 sIL-6R 的优先结合亲和力 (与 mIL-6R 相比) 。Vobarilizumab (0-10 nM) 阻断重组 hIL-6 与重组 hsIL-6R 的相互作用。Vobarilizumab (0-100 nM) 可抑制 TF-1 细胞的增殖。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备